-
Something wrong with this record ?
Protective effect of isoquercitrin against acute dextran sulfate sodium-induced rat colitis depends on the severity of tissue damage
N. Cibiček, L. Roubalová, J. Vrba, M. Zatloukalová, J. Ehrmann, J. Zapletalová, R. Večeřa, V. Křen, J. Ulrichová,
Language English Country Poland
Document type Journal Article
- MeSH
- Colitis chemically induced pathology prevention & control MeSH
- Rats MeSH
- Random Allocation MeSH
- Protective Agents therapeutic use MeSH
- Rats, Wistar MeSH
- Quercetin analogs & derivatives therapeutic use MeSH
- Dextran Sulfate toxicity MeSH
- Severity of Illness Index * MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Isoquercitrin (quercetin-3-O-β-d-glucopyranoside) is a flavonoid that exhibited antioxidant and anti-inflammatory activities in a number of in vitro and in vivo studies. Experimental evidence from rodent models of inflammatory bowel disease is, however, lacking. This study was designed to examine whether isoquercitrin effectively and dose-dependently attenuates acute dextran sulfate sodium (DSS)-induced rat colitis. METHODS: Wistar rats were divided into negative control group (exposed to vehicle only), positive control group (DSS-induced colitis plus vehicle), low isoquercitrin group (DSS pretreated with isoquercitrin 1mg/kg/day) and high isoquercitrin group (DSS with isoquercitrin 10mg/kg/day). Isoquercitrin was administered daily for 14days, and during the last 7days rats drank DSS solution. The effect of isoquercitrin on DSS-induced colitis was assessed clinically (e.g. disease activity index), biochemically (tissue myeloperoxidase activity, local cyclooxygenase-2 expression), using histology (standard hematoxylin-eosin-based histomorphometry, immunohistochemical detection of inducible nitric oxide synthase) and hematology (blood count). RESULTS: Isoquercitrin dose-dependently ameliorated whole colon shortening and mitigated DSS-induced expression of cyclooxygenase-2 and inducible nitric oxide synthase in the descending segment of the organ. However, when different parts of colon were assessed histomorphometrically, the results did not globally support the protective role of this flavonoid. Tissue healing trends observable in the descending colon were not apparent in the rectum, where histological damage was most severe. CONCLUSIONS: We surmise that isoquercitrin may be effective in the prevention of acute colitis. Besides being dose-dependent, the potency of orally administered isoquercitrin may depend on the severity of tissue damage and/or on the site of its action.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013513
- 003
- CZ-PrNML
- 005
- 20170426094508.0
- 007
- ta
- 008
- 170413s2016 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pharep.2016.07.007 $2 doi
- 035 __
- $a (PubMed)27657482
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Cibiček, Norbert $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. Electronic address: norbert.cibicek@upol.cz.
- 245 10
- $a Protective effect of isoquercitrin against acute dextran sulfate sodium-induced rat colitis depends on the severity of tissue damage / $c N. Cibiček, L. Roubalová, J. Vrba, M. Zatloukalová, J. Ehrmann, J. Zapletalová, R. Večeřa, V. Křen, J. Ulrichová,
- 520 9_
- $a BACKGROUND: Isoquercitrin (quercetin-3-O-β-d-glucopyranoside) is a flavonoid that exhibited antioxidant and anti-inflammatory activities in a number of in vitro and in vivo studies. Experimental evidence from rodent models of inflammatory bowel disease is, however, lacking. This study was designed to examine whether isoquercitrin effectively and dose-dependently attenuates acute dextran sulfate sodium (DSS)-induced rat colitis. METHODS: Wistar rats were divided into negative control group (exposed to vehicle only), positive control group (DSS-induced colitis plus vehicle), low isoquercitrin group (DSS pretreated with isoquercitrin 1mg/kg/day) and high isoquercitrin group (DSS with isoquercitrin 10mg/kg/day). Isoquercitrin was administered daily for 14days, and during the last 7days rats drank DSS solution. The effect of isoquercitrin on DSS-induced colitis was assessed clinically (e.g. disease activity index), biochemically (tissue myeloperoxidase activity, local cyclooxygenase-2 expression), using histology (standard hematoxylin-eosin-based histomorphometry, immunohistochemical detection of inducible nitric oxide synthase) and hematology (blood count). RESULTS: Isoquercitrin dose-dependently ameliorated whole colon shortening and mitigated DSS-induced expression of cyclooxygenase-2 and inducible nitric oxide synthase in the descending segment of the organ. However, when different parts of colon were assessed histomorphometrically, the results did not globally support the protective role of this flavonoid. Tissue healing trends observable in the descending colon were not apparent in the rectum, where histological damage was most severe. CONCLUSIONS: We surmise that isoquercitrin may be effective in the prevention of acute colitis. Besides being dose-dependent, the potency of orally administered isoquercitrin may depend on the severity of tissue damage and/or on the site of its action.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kolitida $x chemicky indukované $x patologie $x prevence a kontrola $7 D003092
- 650 _2
- $a síran dextranu $x toxicita $7 D016264
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ochranné látky $x terapeutické užití $7 D020011
- 650 _2
- $a quercetin $x analogy a deriváty $x terapeutické užití $7 D011794
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 12
- $a stupeň závažnosti nemoci $7 D012720
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Roubalová, Lenka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Vrba, Jiří $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Zatloukalová, Martina $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Ehrmann, Jiří $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Zapletalová, Jana $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Večeřa, Rostislav $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Křen, Vladimír $u Institute of Microbiology, Laboratory of Biotransformation, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Ulrichová, Jitka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
- 773 0_
- $w MED00165879 $t Pharmacological reports PR $x 1734-1140 $g Roč. 68, č. 6 (2016), s. 1197-1204
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27657482 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170426094827 $b ABA008
- 999 __
- $a ok $b bmc $g 1199978 $s 974291
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 68 $c 6 $d 1197-1204 $e 20160919 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
- LZP __
- $a Pubmed-20170413
